INKT MINK THERAPEUTICS INC

MiNK Therapeutics to Participate in HC Wainwright Cell Therapy Virtual Conference

MiNK Therapeutics to Participate in HC Wainwright Cell Therapy Virtual Conference

NEW YORK, Feb. 16, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, announced that Dr. Jennifer Buell, President and CEO of MiNK, will participate in a fireside chat at the HC Wainwright Cell Therapy Virtual Conference on February 28th, at 9:00 AM ET.

Access to the live fireside chat is available at . Following the fireside chat, a replay will be available on the Events and Presentations page of the MiNK website at .

About MiNK Therapeutics

MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next-generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, visit . Follow us on Twitter @MiNK_iNKT.

Contact

Alexa Buffa

781-674-4428

Investor relations:

Zack Armen

917-362-1370



EN
16/02/2023

Underlying

INKTMINK THERAPEUTICS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on MINK THERAPEUTICS INC

 PRESS RELEASE
Free
INKT MINK THERAPEUTI...

MiNK Therapeutics Presents New Data of allo-iNKT Cell Therapy as a Pot...

MiNK Therapeutics Presents New Data of allo-iNKT Cell Therapy as a Potential Disease-Modifying Approach in Idiopathic Pulmonary Fibrosis at Keystone Symposia Human lung tissue analyses identify iNKT cell depletion as a mechanistic feature of advanced IPFFindings extend MiNK’s iNKT platform into chronic fibrotic lung disease and support immune restoration strategies in IPF, a large unmet-need market LEXINGTON, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics (Nasdaq: INKT) today announced that new translational data supporting the role of invariant natural killer T (iNKT) cells ...

February 4, 2026 1 EN
 PRESS RELEASE
Free
INKT MINK THERAPEUTI...

MiNK Therapeutics and University of Wisconsin–Madison Announce Phase 1...

MiNK Therapeutics and University of Wisconsin–Madison Announce Phase 1 Clinical Trial of Allo-iNKT Cell Therapy (AgenT-797) to Evaluate Prevention of Graft-Versus-Host Disease Non-dilutive public-private funded trial with NIAID STTR & Mary Gooze Clinical Trial and Translation AwardExpands iNKT platform into transplantation with an off-the-shelf, HLA-independent, lymphodepletion-free experimental therapy in patients at risk for GvHD NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) -- , Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering off-the-shelf allogeneic invariant na...

January 8, 2026 1 EN
 PRESS RELEASE
Free
INKT MINK THERAPEUTI...

MiNK Therapeutics Announces New Data Showing MiNK-215 Drives Potent An...

MiNK Therapeutics Announces New Data Showing MiNK-215 Drives Potent Anti-Tumor Activity in Treatment-resistant Solid Tumors MiNK-215, an IL-15 armoured FAP-targeting CAR-iNKT, targets and clears tumor-protective FAP+ fibroblasts to allow immune cells to infiltrate and kills cancer cellsActivates multiple immune pathways to generate potent, lasting anti-tumor activity in lung and MSS colorectal cancer models NEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) -- , Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies to...

November 20, 2025 1 EN
 PRESS RELEASE
Free
INKT MINK THERAPEUTI...

MiNK Therapeutics Reports Q3 2025 Results and Accelerates iNKT Platfor...

MiNK Therapeutics Reports Q3 2025 Results and Accelerates iNKT Platform Toward Pivotal Development Across Oncology, Pulmonary Disease, and Transplantation New clinical data show durable remissions and long-tail survivors including >2-year complete remissions in chemotherapy- and checkpoint-refractory cancersGVHD trial launching through non-dilutive funding from NIH- and philanthropic grantsLaunching Phase 2+ trial in severe pulmonary disease in US population with FDA-validated endpointsAdded national leaders in pulmonary medicine, trauma, and biodefense join MiNK management (Dr. Hammond) an...

November 14, 2025 1 EN
 PRESS RELEASE
Free
INKT MINK THERAPEUTI...

MiNK Therapeutics Reports Durable Responses and Immune Reactivation wi...

MiNK Therapeutics Reports Durable Responses and Immune Reactivation with Allo-iNKT Cell Therapy agenT-797 in PD-1–Refractory Solid Tumors at SITC 2025 Durable survival and deep, lasting remissions in checkpoint-refractory, heavily pretreated cancers with median OS of ~23 months with agenT-797 plus anti-PD-1Evidence of immune activation and tumor-immune remodeling underscore agenT-797’s potential to restore responsiveness in PD-1–resistant diseaseFavorable safety and reproducible activity reinforce MiNK’s leadership in allogeneic iNKT cell therapy NEW YORK, Nov. 07, 2025 (GLOBE NEWSWIRE) ...

November 7, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch